Antonio Llombart-Cussac

Aug 13, 2024 | onclive.com | Antonio Llombart-Cussac

CommentaryVideoAugust 13, 2024Author(s):Antonio Llombart-Cussac, MD, PhD, on the implications of prophylaxis for sacituzumab govitecan–related neutropenia and diarrhea in advanced breast cancer.

Jun 28, 2024 | onclive.com | Antonio Llombart-Cussac

CommentaryVideoJune 28, 2024Author(s):Antonio Llombart-Cussac, MD, PhD, discusses preventing neutropenia and diarrhea with sacituzumab govitecan in HR+/HER2– advanced breast cancer.

Dec 5, 2023 | emjreviews.com | Antonio Llombart-Cussac |Virginia Kaklamani |Volkmar Müller

Introduction Over 70% of breast cancers are ER+/HER2-, for which the backbone of treatment is endocrine therapy.1-3 Endocrine therapies for ER+/HER2- advanced breast cancer at 1L include aromatase inhibitors, such as anastrozole, letrozole, and exemestane; selective oestrogen receptor modulators, such as tamoxifen; and SERDs, such as fulvestrant.4 Antonio Llombart-Cussac, Head of Medical Oncology at the Arnau de Vilanova Hospital in Valencia, Spain, emphasised that the addition of CDK4/6...